Abstract: The invention relates to an in vitro method for isolating nucleic acids associated to or contained inside extracellular vesicles (EVs) from a sample based on the formation of a DMB-EVs precipitate and the isolation of the nucleic acids present in the precipitate. The invention also relates to the use of the method of the invention for diagnosing or for determining the susceptibility of a subject to a disease, for determining the prognosis or for monitoring the progression of a disease, for monitoring the effect of a therapy, for identifying compounds suitable for the treatment of a disease, or for designing a personalized therapy or selecting a patient susceptible to being treated with a therapy for the prevention and/or treatment of a disease. In addition, the invention also relates to a kit comprising dimethylmethylene blue (DMB) and a reagent capable of isolating nucleic acids from EVs, and to its use.

Abstract: The present invention relates to a composition for modulating tumor cell dissemination, in particular metastatic cancer cells. In particular, the invention relates to an agent for modulating metastatic tumor cell dissemination for use in the treatment and/or prevention of a metastatic cancer wherein the agent comprises an extracellular matrix (ECM) protein carried on a polycarbonate polyurethane matrix, and wherein the agent binds to tumor cells when implanted in a body. The invention also relates to a product, comprising an agent for modulating metastatic tumor cell dissemination, and to a method of treatment or prevention of cancer.

Abstract: The present invention relates to a composition for modulating tumor cell dissemination, in particular metastatic cancer cells. In particular, the invention relates to an agent for modulating metastatic tumor cell dissemination for use in the treatment and/or prevention of a metastatic cancer wherein the agent is a capture agent and/or a chemoattractant for tumor cells. The invention also relates to a product, comprising an agent for modulating metastatic tumor cell dissemination, and to a method of treatment or prevention of cancer.

Abstract: The present invention relates to a composition for modulating tumor cell dissemination, in particular metastatic cancer cells. In particular, the invention relates to an agent for modulating metastatic tumor cell dissemination for use in the treatment and/or prevention of a metastatic cancer wherein the agent an extracellular matrix (ECM) protein carried on a polycarbonate polyurethane matrix. The invention also relates to a product, comprising an agent for modulating metastatic tumor cell dissemination, and to a method of treatment or prevention of cancer.

Abstract: The present invention relates to a composition for modulating tumor cell dissemination, in particular metastatic cancer cells. In particular, the invention relates to an agent for modulating metastatic tumor cell dissemination for use in the treatment and/or prevention of a metastatic cancer wherein the agent an extracellular matrix (ECM) protein carried on a polycarbonate polyurethane matrix. The invention also relates to a product, comprising an agent for modulating metastatic tumor cell dissemination, and to a method of treatment or prevention of cancer.

Abstract: The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected and individuals.

Abstract: The present invention relates to a composition for modulating tumor cell dissemination, in particular metastatic cancer cells. In particular, the invention relates to an agent for modulating metastatic tumor cell dissemination for use in the treatment and/or prevention of a metastatic cancer wherein the agent is a capture agent and/or a chemoattractant for tumor cells. The invention also relates to a product, comprising an agent for modulating metastatic kidneys tumor cell dissemination, and to a method of treatment or prevention of cancer.

Abstract: The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.

Abstract: The invention relates to methods and kits for the diagnosis of prostate cancer (PCa) in a subject, for assessing or monitoring the response to a therapy in a subject having PCa or for monitoring the progression of prostate cancer PCa based on the detection of alteration in the expression levels of at least one gene selected from the group of PC A3, PSMA and PSGR. The invention relates as well to methods for assessing whether a subject has to be subjected to a prostate biopsy, said subject having a serum PSA range within 4-10 ng/mL.

Abstract: The present invention relates to the use of PSGR, a member of the G-protein-coupled olfactory receptor family which is over-expressed in prostate cancer tissue, as a marker suitable for an urine-based diagnostic test for prostate cancer which require only typical prostate manipulation and sample acquisition scenarios avoiding invasive tissue collection.

Abstract: The invention relates to the surprising finding that biomarkers corresponding to ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1 R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, S0CS2, and DCN are differentially expressed in control samples as compared to samples from patients having endometrial cancer and are therefore useful for detecting endometrial cancer. In particular these biomarkers having excellent sensitivity, specificity, and/or the ability to separate affected from non affected individuals. Furthermore, the inventors found that the differential expression of these biomarkers in primary endometrial cancer tumor tissue is correlated to their expression level in uterine fluid samples as compared to control values. Thus these biomarkers are robust in that they are found to be differentially expressed in several different types of samples from affected individuals.